WASHINGTON, July 1, 2003 (PRIMEZONE) -- Growth Report, an independent investment newsletter service that has delivered to our loyal readers an overall return of 38% for the first half of 2003, today announced the release of an updated Special Report on three Generic and Specialty Pharmaceutical companies and the industry as a whole.
The Special Report titled "Not So Generic Returns -- Investing in Generic and Specialty Pharmaceuticals" discusses general factors that are expected to drive growth in this entire sector in the coming years, as well as three specific companies that Growth Report Editor Ian Wyatt believes could be top-performing small cap investments.
The three companies evaluated by Growth Report are aaiPharma (Nasdaq:AAII), Bentley Pharmaceuticals (AMEX:BNT), and Impax Laboratories (Nasdaq:IPXL).
Wyatt commented on the sector, saying, "The generic and specialty pharmaceutical business is an over-looked, high growth sector. It will continue to see significant upside, given the favorable political and consumer pressures for lower cost prescription drugs from an aging baby-boomer population. There are few companies in this arena that I believe are poised to deliver significant returns to investors in the coming years."
Growth Report's three picks in this sector have already delivered an average return of 41%. Wyatt believes all three could appreciate by at least another 20% over the next 12-months, given the recent interest by investors, consumers, and politicians, and increased valuations for generic pharmaceutical companies as a whole.
Growth Report covers aaiPharma, Bentley Pharmaceuticals, and Impax Laboratories in its model portfolio.
Free trial and paid subscribers can view Growth Report's current comments on these companies and receive this Special Report on the Internet at www.growthreport.com .
Growth Report's stock portfolio returned 40% in 2002, and is up another 38% in the first half of 2003 by taking long-term positions in fundamentally strong growth stocks. This investment approach had yielded consistently strong returns for subscribers of the newsletter service.
Individual investors who are interested in signing up for a 30-day free trial to Growth Report will receive the free Special Report titled "Not So Generic Returns -- Investing in Generic and Specialty Pharmaceuticals" that details three stocks in this sector. Free trial subscribers also receive two issues per week by e-mail, one issue per month in print, access to over one year of archived articles, and past and future Special Reports. To start a free 30-day trial subscription, click here: https://www.bizfn.com/index.cfm?Page=pubs&pubs=2&r=pr2
About Growth Report
Growth Report is a leading investment newsletter service published by Business Financial Publishing, LLC. Growth Report is entirely independent, and dedicated to uncovering stocks that will deliver the greatest return to subscribers. Two weekly issues delivered by e-mail and on the web provide subscribers with regular updates on the latest news and changes to the portfolio, while a monthly print edition provides in depth articles in an easy to read format.
Disclaimer
Growth Report, LLC, is neither a registered investment advisor nor a broker / dealer. Readers are advised that the publication is issued solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. No information provided herein or elsewhere from Growth Report constitutes a recommendation by Growth Report to buy, sell or hold any security. We encourage you to consult with independent financial advisors with respect to any investment in the securities mentioned herein.